Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 6/20 | 0.61 |
| ▸ | MAOA | P21397 | 5/20 | 0.61 |
| ▸ | RXRA | P19793 | 2/20 | 0.52 |
| ▸ | RXRB | P28702 | 2/20 | 0.52 |
| ▸ | RXRG | P48443 | 2/20 | 0.52 |
| ▸ | PPARG | P37231 | 3/20 | 0.52 |
| ▸ | PPARD | Q03181 | 3/20 | 0.52 |
| ▸ | PPARA | Q07869 | 3/20 | 0.52 |
| ▸ | HRH3 | Q9Y5N1 | 5/20 | 0.51 |
| ▸ | KDM1A | O60341 | 1/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | REN | P00797 | 1/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.48 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6225615 | 0.90 | MAOB (0.63) | MAOBMAOARXRARXRBRXRG | |
| SCHEMBL4717674 | 0.90 | MAOB (0.66) | MAOBMAOAHRH3ALOX5 | |
| SCHEMBL6421129 | 0.85 | MAOA (0.64) | MAOBMAOAHRH3KDM1ACYP2D6 | |
| SCHEMBL30299191 | 0.82 | HRH3 (0.72) | MAOBMAOARXRARXRBRXRG | |
| SCHEMBL5469125 | 0.81 | HRH3 (0.45) | MAOBMAOAPPARGPPARDPPARA | |
| SCHEMBL15413967 | 0.80 | MAOB (0.85) | MAOBMAOA | |
| SCHEMBL3875255 | 0.79 | MAOA (0.68) | MAOBMAOAHRH3ALOX5 | |
| SCHEMBL12472442 | 0.79 | HRH3 (0.72) | MAOBMAOARXRARXRBRXRG | |
| Hydrochloric Acid SCHEMBL3902331 | 0.78 | MAOA (0.66) | MAOBMAOAHRH3ALOX5 | |
| SCHEMBL15897930 | 0.77 | MAOA (0.50) | MAOBMAOAPPARGPPARDPPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1347967-B1 | NOVEL BENZAZEPINES AND RELATED HETEROCYCLIC DERIVATIVES WHICH ARE USEFUL AS OREXIN RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2007-12-19 | — | — | EP | disclosed |
| US-7192950-B2 | Benzazepines and related heterocyclic derivatives which are useful as orexin receptor antagonists | ACTELION PHARMACEUTICALS, LTD. (CH) | 2007-03-20 | — | — | US | disclosed |
| US-20040058912-A1 | Novel benzazepines and related heterocyclic derivatives which are useful as orexin receptor antagonists | ACTELION PHARMACEUTICALS LTD. (CH) | 2004-03-25 | — | — | US | disclosed |
| EP-1347967-A1 | NOVEL BENZAZEPINES AND RELATED HETEROCYCLIC DERIVATIVES WHICH ARE USEFUL AS OREXIN RECEPTOR ANTAGONISTS | Actelion Pharmaceuticals Ltd. (CH) | 2003-10-01 | — | — | EP | disclosed |
| WO-2002051232-A2 | NOVEL BENZAZEPINES AND RELATED HETEROCYCLIC DERIVATIVES | ACTELION PHARMACEUTICALS LTD. (CH) | 2002-07-04 | — | — | WO | disclosed |
| WO-2002051838-A1 | NOVEL BENZAZEPINES AND RELATED HETEROCYCLIC DERIVATIVES WHICH ARE USEFUL AS OREXIN RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD. (CH) | 2002-07-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040058912-A1 | Novel benzazepines and related heterocyclic derivatives which are useful as orexin receptor antagonists | HCRTR2, HCRTR1, OXTR | MAOB 251/4885MAOA 293/4885RXRA 1230/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.